{"id":866634,"date":"2025-07-03T17:39:07","date_gmt":"2025-07-03T21:39:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/"},"modified":"2025-07-03T17:39:07","modified_gmt":"2025-07-03T21:39:07","slug":"organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/","title":{"rendered":"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">PHILADELPHIA<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 3, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4462219-1&amp;h=1279172986&amp;u=https%3A%2F%2Fbergermontague.com%2F&amp;a=Berger+Montague+PC\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Berger Montague PC<\/span><\/a>\u00a0advises investors that a securities class action lawsuit has been filed against <b>Organon &amp; Co.<\/b> (&#8220;Organon&#8221; or the &#8220;Company&#8221;) (NYSE: OGN) on behalf of purchasers of Organon\u00a0securities between<b>\u00a0October 31, 2024 through <span class=\"xn-chron\">April 30<\/span>, 2025,\u00a0<\/b>inclusive (the &#8220;Class Period&#8221;).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" title=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" alt=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <i>Investor Deadline: Investors who purchased or acquired <\/i><br \/>\n        <b>Organon<\/b><br \/>\n        <i>\u00a0securities during the Class Period may, no later than <\/i><br \/>\n        <u><br \/>\n          <span class=\"xn-chron\">JULY 22, 2025<\/span><br \/>\n        <\/u><br \/>\n        <i>, seek to be appointed as a lead plaintiff representative of the class. <b>To learn your rights, <\/b><\/i><br \/>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4462219-1&amp;h=2209082420&amp;u=https%3A%2F%2Finvestigations.bergermontague.com%2Forganon-co%2F&amp;a=CLICK+HERE\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b><br \/>\n            <i>CLICK HERE<\/i><br \/>\n          <\/b><br \/>\n        <\/a><br \/>\n        <b><br \/>\n          <i>.<\/i><br \/>\n        <\/b>\n      <\/p>\n<p>Organon, headquartered in <span class=\"xn-location\">Jersey City, NJ<\/span>, is a healthcare company focused on women&#8217;s health. In <span class=\"xn-chron\">October 2024<\/span>, Organon acquired Dermavant, a biopharmaceutical company focused on dermatological conditions, for <span class=\"xn-money\">$1.2 billion<\/span>.<\/p>\n<p>According to the lawsuit, despite the increase in debt from the Dermavant acquisition, the Company assured investors that it would maintain its dividend, which it described as its &#8220;#1 capital allocation priority.&#8221;<\/p>\n<p>On <span class=\"xn-chron\">May 1, 2025<\/span>, investors learned the truth when Organon announced that management reset the Company&#8217;s dividend payout from <span class=\"xn-money\">$0.28<\/span> per share to <span class=\"xn-money\">$0.02<\/span> per share. Organon&#8217;s senior management explained that the Company had &#8220;reset our capital allocation priorities to accelerate progress towards deleveraging&#8221; and that &#8220;returning capital to shareholders is right now, less of a priority.&#8221;<\/p>\n<p>On this news, the price of Organon stock declined <span class=\"xn-money\">$3.48<\/span> per share \u2013 approximately 27% \u2013 from a closing price of <span class=\"xn-money\">$12.93<\/span> per share on <span class=\"xn-chron\">April 30, 2025<\/span> to a close of <span class=\"xn-money\">$9.45<\/span> per share on <span class=\"xn-chron\">May 1, 2025<\/span>.<\/p>\n<p>\n        <b><br \/>\n          <i>To learn your rights or for more information, <\/i><br \/>\n        <\/b><br \/>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4462219-1&amp;h=2209082420&amp;u=https%3A%2F%2Finvestigations.bergermontague.com%2Forganon-co%2F&amp;a=CLICK+HERE\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b><br \/>\n            <i>CLICK HERE<\/i><br \/>\n          <\/b><br \/>\n        <\/a><br \/>\n        <b><br \/>\n          <i> or please contact <span class=\"xn-person\">Berger Montague<\/span>: <span class=\"xn-person\">Andrew Abramowitz<\/span> at <\/i><br \/>\n        <\/b><br \/>\n        <a href=\"mailto:aabramowitz@bm.net\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b><br \/>\n            <i>aabramowitz@bm.net<\/i><br \/>\n          <\/b><br \/>\n        <\/a><br \/>\n        <b><br \/>\n          <i>\u00a0or (215) 875-3015, or <span class=\"xn-person\">Peter Hamner<\/span> at <\/i><br \/>\n        <\/b><br \/>\n        <a href=\"mailto:phamner@bm.net\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b><br \/>\n            <i>phamner@bm.net<\/i><br \/>\n          <\/b><br \/>\n        <\/a>.<\/p>\n<p>A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his\/her choice, or may choose to do nothing and remain an inactive class member.<\/p>\n<p>\n        <span class=\"xn-person\">Berger Montague<\/span>, with offices in <span class=\"xn-location\">Philadelphia<\/span>, <span class=\"xn-location\">Minneapolis<\/span>, <span class=\"xn-location\">Delaware<\/span>, <span class=\"xn-location\">Washington, D.C.<\/span>, <span class=\"xn-location\">San Diego<\/span>, <span class=\"xn-location\">San Francisco<\/span> and <span class=\"xn-location\">Chicago<\/span>, has been a pioneer in <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4462219-1&amp;h=2052127117&amp;u=https%3A%2F%2Fbergermontague.com%2Fsecurities%2F&amp;a=securities+class+action+litigation\" target=\"_blank\" rel=\"nofollow\">securities class action litigation<\/a> since its founding in 1970. <span class=\"xn-person\">Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>Contact:<\/p>\n<p>\n        <span class=\"xn-person\">Andrew Abramowitz<\/span>, Senior Counsel<br \/><span class=\"xn-person\">Berger Montague<\/span><br \/>(215) 875-3015<br \/><a href=\"mailto:aabramowitz@bm.net\" target=\"_blank\" rel=\"nofollow\">aabramowitz@bm.net<\/a>\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Peter Hamner<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">Berger Montague PC<\/span><br \/>\n        <br \/>\n        <a href=\"mailto:phamner@bm.net\" target=\"_blank\" rel=\"nofollow\">phamner@bm.net<\/a>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC23936&amp;sd=2025-07-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/organon--co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit-302497855.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/organon&#8211;co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit-302497855.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Berger Montague<\/span><\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC23936&amp;Transmission_Id=202507031736PR_NEWS_USPR_____DC23936&amp;DateId=20250703\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PHILADELPHIA , July 3, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC\u00a0advises investors that a securities class action lawsuit has been filed against Organon &amp; Co. (&#8220;Organon&#8221; or the &#8220;Company&#8221;) (NYSE: OGN) on behalf of purchasers of Organon\u00a0securities between\u00a0October 31, 2024 through April 30, 2025,\u00a0inclusive (the &#8220;Class Period&#8221;). Investor Deadline: Investors who purchased or acquired Organon \u00a0securities during the Class Period may, no later than JULY 22, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Organon, headquartered in Jersey City, NJ, is a healthcare company focused on women&#8217;s health. In October 2024, Organon acquired Dermavant, a biopharmaceutical company focused on dermatological conditions, for $1.2 billion. According to the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866634","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , July 3, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC\u00a0advises investors that a securities class action lawsuit has been filed against Organon &amp; Co. (&#8220;Organon&#8221; or the &#8220;Company&#8221;) (NYSE: OGN) on behalf of purchasers of Organon\u00a0securities between\u00a0October 31, 2024 through April 30, 2025,\u00a0inclusive (the &#8220;Class Period&#8221;). Investor Deadline: Investors who purchased or acquired Organon \u00a0securities during the Class Period may, no later than JULY 22, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Organon, headquartered in Jersey City, NJ, is a healthcare company focused on women&#8217;s health. In October 2024, Organon acquired Dermavant, a biopharmaceutical company focused on dermatological conditions, for $1.2 billion. According to the &hellip; Continue reading &quot;Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-03T21:39:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit\",\"datePublished\":\"2025-07-03T21:39:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/\"},\"wordCount\":508,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/\",\"name\":\"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-07-03T21:39:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , July 3, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC\u00a0advises investors that a securities class action lawsuit has been filed against Organon &amp; Co. (&#8220;Organon&#8221; or the &#8220;Company&#8221;) (NYSE: OGN) on behalf of purchasers of Organon\u00a0securities between\u00a0October 31, 2024 through April 30, 2025,\u00a0inclusive (the &#8220;Class Period&#8221;). Investor Deadline: Investors who purchased or acquired Organon \u00a0securities during the Class Period may, no later than JULY 22, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Organon, headquartered in Jersey City, NJ, is a healthcare company focused on women&#8217;s health. In October 2024, Organon acquired Dermavant, a biopharmaceutical company focused on dermatological conditions, for $1.2 billion. According to the &hellip; Continue reading \"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-03T21:39:07+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit","datePublished":"2025-07-03T21:39:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/"},"wordCount":508,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/","name":"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-07-03T21:39:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-co-nyse-ogn-deadline-approaching-berger-montague-advises-investors-of-deadline-in-securities-fraud-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Organon &amp; Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866634"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866634\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}